Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darovasertib + Crizotinib in HLA-A2 Negative Metastatic Uveal Melanoma
NCT05987332Phase 3Active, not recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Oct 2023
- Primary completion
- Jan 2027
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of darovasertib in Uveal melanoma (UM), sponsored by IDEAYA Biosciences. Primary endpoints: Optimal dose of IDE196 + Crizotinib at 5 months, Progression-Free Survival at 2 years and 1 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
darovasertib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05987332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987332.